Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director · President & CEO | May 29, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date May 29, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.70 · Expires 2027-08-06 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-29 · Disposition to issuer · Disposed 200,000 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2028-02-01 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.37 · Expires 2029-01-11 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Disposition to issuer · Disposed 450,000 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.73 · Expires 2030-01-10 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Disposition to issuer · Disposed 500,000 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.33 · Expires 2031-01-23 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-29 · Disposition to issuer · Disposed 500,000 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-29 · Disposition to issuer · Disposed 125,000 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.94 · Expires 2032-01-04 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-29 · Disposition to issuer · Disposed 402,500 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.37 · Expires 2033-01-05 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-29 · Disposition to issuer · Disposed 402,500 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F2: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.44 · Expires 2033-06-13 | Direct | 0 |
Reported balance
After 2026-05-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-29 · Disposition to issuer · Disposed 225,000 · Balance 0 F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 200,000 |
Reported balance
After 2026-05-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-29 · Grant · Acquired 200,000 · Balance 200,000 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 400,000 |
Reported balance
After 2026-05-29 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-29 · Grant · Acquired 400,000 · Balance 400,000 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 450,000 |
Reported balance
After 2026-05-29 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-29 · Grant · Acquired 450,000 · Balance 450,000 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 500,000 |
Reported balance
After 2026-05-29 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-05-29 · Grant · Acquired 500,000 · Balance 500,000 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 500,000 |
Reported balance
After 2026-05-29 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-05-29 · Grant · Acquired 500,000 · Balance 500,000 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 125,000 |
Reported balance
After 2026-05-29 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-05-29 · Grant · Acquired 125,000 · Balance 125,000 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 402,500 |
Reported balance
After 2026-05-29 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-05-29 · Grant · Acquired 402,500 · Balance 402,500 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 402,500 |
Reported balance
After 2026-05-29 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-05-29 · Grant · Acquired 402,500 · Balance 402,500 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F2: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-05-29 | Direct | 225,000 |
Reported balance
After 2026-05-29 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-05-29 · Grant · Acquired 225,000 · Balance 225,000 F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
F2: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F3: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
F4: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 18 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 402,500 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 17 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,500 Underlying: Common Stock · 402,500 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 402,500 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 16 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,500 Underlying: Common Stock · 402,500 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 15 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 14 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 13 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 450,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 12 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 11 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $1.59 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 10 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-05-29 F4 · derivative.exercise_price: On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027. F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 9 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2033-06-13 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 402,500 | Not disclosed Strike: $10.37 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 8 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 402,500 shares Expires 2033-01-05 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 402,500 | Not disclosed Strike: $15.94 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 7 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 402,500 shares Expires 2032-01-04 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $17.60 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 6 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2031-02-01 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $18.33 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 5 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2031-01-23 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 500,000 | Not disclosed Strike: $17.73 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 4 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2030-01-10 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 450,000 | Not disclosed Strike: $12.37 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 3 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2029-01-11 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $10.05 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 2 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2028-02-01 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 00:29 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $12.70 | Not disclosed |
DisclosureSEC source: 0001104659-26-069621 · tm2616725-1_4seq1.xml · derivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2027-08-06 F3 · price: On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 21:40 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001610717-26-000027 · form4.xml · derivative · entry 4 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2036-01-23 F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 23, 2026 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 21:40 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 375,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000027 · form4.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,048,235 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest on May 20, 2027 and 50% of the RSUs vest on March 20, 2029, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 20, 2026 Filed Jan 23, 2026 01:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 11,839 | $1.55 | $18,350.45 |
DisclosureSEC source: 0001610717-26-000016 · form4.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,235 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:58 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001610717-25-000116 · form4.xml · derivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2035-05-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of May 7, 2025 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 20, 2025 Filed Jan 23, 2025 00:48 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 11,810 | $1.39 | $16,415.90 |
DisclosureSEC source: 0001610717-25-000013 · form4.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 685,074 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:21 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 575,000 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001610717-25-000011 · form4.xml · derivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2035-01-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 10, 2025 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 04, 2025 Filed Jan 8, 2025 01:52 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 11,810 | $1.66 | $19,604.60 |
DisclosureSEC source: 0001610717-25-000009 · form4.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696,884 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. Read SEC document |
| July 22, 2024 Filed Jul 25, 2024 00:16 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 196,500 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001610717-24-000406 · form4.xml · derivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,500 Underlying: Common Stock · 196,500 shares Expires 2034-04-11 F1 · derivative.exercise_date: On April 11, 2024 the Reporting Person was granted a performance stock option to purchase 982,500 shares of common stock, of which 196,500 of the shares vested and became exercisable on July 22, 2024 in connection with the Closing of the sale of Coherus BioSciences, Inc.'s YUSIMRY franchise. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 01:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 11,218 | $2.44 | $27,371.92 |
DisclosureSEC source: 0001610717-24-000039 · form4.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 708,694 F1 · shares: Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 00:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 575,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001610717-24-000019 · form4.xml · derivative · entry 4 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 575,000 shares Expires 2034-01-05 F4 · derivative.exercise_date: 1/48th of the total number of shares subject to the option shall vest in successive, equal monthly installments measured from January 5, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 04, 2024 Filed Jan 9, 2024 00:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 11,781 | $2.92 | $34,400.52 |
DisclosureSEC source: 0001610717-24-000019 · form4.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,912 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 299,940 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001610717-23-000363 · form4.xml · derivative · entry 6 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 299,940 shares Expires 2023-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The underlying shares subject to the option vested and became exercisable in successive, equal monthly installments over four years measured from July 20, 2013. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 223,100 | $2.02 | $449,769.60 |
DisclosureSEC source: 0001610717-23-000363 · form4.xml · nonDerivative · entry 3 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,693 F2 · kind: For the remaining part of the stock option, this represents a cashless exercise-and-hold transaction where only enough shares were sold to cover the exercise price, anticipated taxes and broker's fee, and the remaining shares were held by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $2.000 to $2.055. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 258,940 | $1.42 | $366,917.98 |
DisclosureSEC source: 0001610717-23-000363 · form4.xml · nonDerivative · entry 2 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 954,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: For the remaining part of the stock option, this represents a cashless exercise-and-hold transaction where only enough shares were sold to cover the exercise price, anticipated taxes and broker's fee, and the remaining shares were held by the Reporting Person. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 21:04 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 41,000 | $1.42 | $58,097.00 |
DisclosureSEC source: 0001610717-23-000363 · form4.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: For part of the stock option, this represents a cash exercise-and-hold transaction where cash was paid by the Reporting Person for the exercise price and anticipated taxes. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:42 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001610717-23-000168 · form4.xml · derivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 50% of the shares on each anniversary measured from June 13, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 86,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-001211 · doc1.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,853 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 20 of each year, with the first 1/3 vesting on January 20, 2024 and with the RSUs being fully vested on January 20, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 23:17 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 402,500 | $0.00 Strike: $10.37 | $0.00 |
DisclosureSEC source: 0001567619-23-000698 · doc1.xml · derivative · entry 4 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,500 Underlying: Common Stock · 402,500 shares Expires 2033-01-05 F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 23:17 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock | 10,905 | $9.87 | $107,632.35 |
DisclosureSEC source: 0001567619-23-000698 · doc1.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,603 F1 · shares: Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 23:44 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000350 · doc1.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 432,684 F1 · ownership.nature: These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 00:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 402,500 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0001567619-22-000821 · doc1.xml · derivative · entry 4 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,500 Underlying: Common Stock · 402,500 shares Expires 2032-01-04 F5 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 04, 2022 Filed Jan 7, 2022 00:50 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 86,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000821 · doc1.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,508 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 86,250 RSUs. Read SEC document |
| November 17, 2021 Filed Nov 23, 2021 22:00 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-021059 · doc1.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 436,684 F1 · kind: Gift for charitable purposes of 10,000 shares of the Company's Common Stock to a private trust. The private trust is not owned or controlled by the Reporting Person or the Reporting Person's family members and no compensation was received in return for the gift of the shares. F2 · ownership.nature: These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee. Read SEC document |
| June 08, 2021 Filed Jun 8, 2021 21:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,054 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001567619-21-011842 · doc1.xml · derivative · entry 7 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,054 shares Expires 2021-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 08, 2021 Filed Jun 8, 2021 21:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock | 31,054 | $13.56 | $421,228.88 |
DisclosureSEC source: 0001567619-21-011842 · doc1.xml · nonDerivative · entry 3 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,258 F3 · price: The transaction was executed in multiple trades in prices ranging from $13.55 to $13.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2021 Filed Jun 8, 2021 21:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 31,054 | $0.42 | $12,943.31 |
DisclosureSEC source: 0001567619-21-011842 · doc1.xml · nonDerivative · entry 2 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2021 Filed Jun 8, 2021 21:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001567619-21-011842 · doc1.xml · derivative · entry 6 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,054 Underlying: Common Stock · 300,000 shares Expires 2021-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 06, 2021 Filed Jun 8, 2021 21:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock | 300,000 | $0.42 | $125,040.00 |
DisclosureSEC source: 0001567619-21-011842 · doc1.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:38 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $17.60 | $0.00 |
DisclosureSEC source: 0001567619-21-002142 · doc1.xml · derivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: On January 23, 2021, the board of directors of Coherus BioSciences, Inc. approved the grant of an option to purchase 125,000 shares of common stock subject to the achievement of a certain performance milestone. 100% of the shares underlying this option were fully vested and exercisable at grant. Read SEC document |
| January 23, 2021 Filed Jan 26, 2021 21:37 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $18.33 | $0.00 |
DisclosureSEC source: 0001567619-21-001529 · doc1.xml · derivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-01-23 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 23, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:58 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,994 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001567619-20-012977 · doc1.xml · derivative · entry 4 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,994 shares Expires 2020-10-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 21:58 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 29,994 | $0.01 | $248.95 |
DisclosureSEC source: 0001567619-20-012977 · doc1.xml · nonDerivative · entry 1 Lanfear Dennis M · CIK 0001420822 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.